Sierra Oncology Inc
NASDAQ:SRRA
Sierra Oncology Inc
Cash from Financing Activities
Sierra Oncology Inc
Cash from Financing Activities Peer Comparison
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Sierra Oncology Inc
NASDAQ:SRRA
|
Cash from Financing Activities
$254.3m
|
CAGR 3-Years
259%
|
CAGR 5-Years
56%
|
CAGR 10-Years
N/A
|
|
Zymeworks Inc
NYSE:ZYME
|
Cash from Financing Activities
$81.8m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
Repare Therapeutics Inc
NASDAQ:RPTX
|
Cash from Financing Activities
$842k
|
CAGR 3-Years
-85%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Fusion Pharmaceuticals Inc
NASDAQ:FUSN
|
Cash from Financing Activities
$142m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
51%
|
CAGR 10-Years
N/A
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Cash from Financing Activities
-$5.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Spectral Medical Inc
TSX:EDT
|
Cash from Financing Activities
CA$5.4m
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-1%
|
See Also
What is Sierra Oncology Inc's Cash from Financing Activities?
Cash from Financing Activities
254.3m
USD
Based on the financial report for Mar 31, 2022, Sierra Oncology Inc's Cash from Financing Activities amounts to 254.3m USD.
What is Sierra Oncology Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
56%
Over the last year, the Cash from Financing Activities growth was 763%. The average annual Cash from Financing Activities growth rates for Sierra Oncology Inc have been 259% over the past three years , 56% over the past five years .